Trial Profile
Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade or Standard Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms ENCORE
- Sponsors Merck Sharp & Dohme Corp.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
- 10 Oct 2009 New trial record.